Arecor Therapeutics (LON:AREC) Shares Down 3.1% – Should You Sell?

Arecor Therapeutics plc (LON:AREC)’s share price was down 3.1% on Friday . The company traded as low as GBX 60.12 and last traded at GBX 61.50. Approximately 59,482 shares changed hands during trading, an increase of 201% from the average daily volume of 19,749 shares. The stock had previously closed at GBX 63.50.

Arecor Therapeutics Trading Down 3.1%

The firm has a market cap of £23.22 million, a P/E ratio of 30.75 and a beta of -0.18. The company has a debt-to-equity ratio of 1.52, a quick ratio of 6.24 and a current ratio of 4.35. The firm has a fifty day moving average of GBX 64.09 and a 200-day moving average of GBX 69.29.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.